findmyKOL
Clinical trialNCT00226005CompletedPhase 2Interventional

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

SponsorPancreatic Cancer Research TeamEnrollment67Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer. In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rarely, it might be possible to stop tumor growth without harming normal tissues.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Tomislav Dragovich, MD, PhD

    University of Arizona/Arizona Cancer Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Scottsdale Healthcare

    Scottsdale, Arizona, United States

  • University of Arizona/arizona Cancer Center

    Tucson, Arizona, United States

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California, United States

  • Sidney Kimmel Comprehensive Cancer Center/johns Hopkins

    Baltimore, Maryland, United States

  • Virginia Piper Cancer Institute/abbott Northwestern Hospital

    Minneapolis, Minnesota, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, United States

  • South Texas Oncology and Hematology

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PTK787/ZK222584
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2005
Primary completion
31 Dec 2008
Completion
28 Feb 2010
Last update posted
9 May 2012
Registered enrollment
67
Registry id
NCT00226005

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.